Molecular Determinants for Therapy Response on Renal Cell Carcinoma
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Aim of the scientific analysis is to find biological factors (biomarkers) allowing a
prediction of disease progression and a better choice of therapy. After diagnosis the kidney
and the tumor will be removed by standard surgery followed by drug therapy. Within surgery
remaining tumor tissue will be used for the scientific analysis. In case of disease
progression during the drug treatment the drug therapy will be changed. Before therapy change
a small tissue sample will be collected for molecular diagnostics. This will be done by
puncture through the skin under local anesthesia. Blood samples taken before surgery and at
the time of first and second disease progression will also be used for molecular-biological
analysis. As there is no clear recommendation for drug therapy after disease progression this
study should serve to determine an individual therapy on the basis of the molecular profile
and the molecular changes. As the tumor disease changes and developes resistance to drugs,
analysis at the time of disease progression shall identify biological factors which will
predict a likelihood response to a specific drugs.
This shall allow to give the patient an individual therapy.